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Background
Two consecutively performed randomized studies by the
AMC evaluating chemoimmunotherapy for the treat-
ment of HIV-associated NHL include AMC010 [1]
(Concurrent Rituximab [R] + CHOP vs. CHOP, N=150)
and AMC034 [2] (Concurrent R+EPOCH vs. Sequential
EPOCH ®R; N=106). In AMC010, the addition of
Rituximab to CHOP was associated with an increased
risk of infectious death (15% vs. 2%, p=0.035) without a
significant improvement in complete response (CR) rate
(58% vs. 47%; p=0.147), event-free survival (EFS), or
overall survival (OS). In AMC034, the CR rate met its
primary efficacy endpoint in the concurrent arm (73%;
95% confidence intervals [CI] 58%, 85%) but not the
sequential arm (55%; 95% CI 41%, 68%).
Methods
We performed a pooled analysis of these two consecu-
tive trials including patients treated with R-CHOP and
concurrent R-EPOCH in order to determine the influ-
ence of the age-adjusted International Prognostic Index
(aaIPI), CD4 count (<100/μL vs. >100/μL), and treat-
ment (CHOP vs. EPOCH) as variables.
Results
The characteristics and outcomes of the study popula-
tions are shown in table 1. Patients treated with R-
EPOCH tended to have better outcomes in both the low
and high-risk IPI groups.
In a multivariate analysis that included pooled data
from both consecutive studies, features that were signifi-
cantly associated with improved EFS, OS, and CR rate
included low aaIPI score and baseline CD4 count of at
least 100/μl. Additionally patients treated with concur-
rent R-EPOCH exhibited improved EFS and OS even
when adjusted for prognostic covariates including aaIPI
score and CD4 count (Table 2).
Conclusions
These findings suggest that treatment outcomes may be
superior with concurrent R-EPOCH compared with R-
CHOP, and support the design of an ongoing Phase III
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Table 1 Patient characteristics and outcomes
R-CHOP R-EPOCH
No. 99 51
CD4<100/μL 41% 31%
High aaIPI risk (2-3 factors) 59% 69%
Mean age (years +/- standard
deviation) 43.5 (+ 8.3) 42.6 (+8.4)
CR rate
Low risk aaIPI (0-1 factors)
High risk aaIPI (2-3 factors)
76% (60%, 88%)
45% (32%, 58%)
88% (62%, 98%)
60% (42%, 76%)
2 year EFS
Low risk aaIPI (0-1 factors)
High risk IPI (2-3 factors)
57% (36%, 73%)
30% (18%, 43%)
81% (51%, 93%)
59% (41%, 74%)
2 year OS
Low risk aaIPI (0-1 factors)
High risk aaIPI (2-3 factors)
66% (43%, 82%)
36% (23%, 50%)
87% (57%, 97%)
62%, (44%, 76%)
Barta et al. Infectious Agents and Cancer 2010, 5(Suppl 1):A63
http://www.infectagentscancer.com/content/5/S1/A63
© 2010 Barta et al; licensee BioMed Central Ltd.trial comparing concurrent R-EPOCH with R-CHOP in
immunocompetent patients with diffuse, large B-cell
lymphoma (NCT00118209). This analysis provides addi-
tional level 2 evidence supporting the use of concurrent
R-EPOCH in patients with HIV-associated lymphoma.
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Table 2 Multivariate analysis regarding the outcomes event-free survival (EFS), overall survival (OS) and rate of
complete or unconfirmed complete remission (CR/CRu)
EFS p-value HR (95% CI) OS p-value HR (95% CI) CR/Cru p-value OR (95% CI)
aaIPI score (0-1 vs. 2-3) <0.001 0.32 (0.17, 0.57) <0.001 0.28 (0.14, 0.56) <0.001 4.58 (1.96, 10.69)
CD4 (≥100 vs. < 100/μL <0.001 0.42 (0.26, 0.69) <0.001 0.37 (0.22, 0.63) <0.05 2.70 (1.26, 5.79)
R-EPOCH vs. R-CHOP <0.01 0.40 (0.23,0.69) <0.01 0.38 (0.21, 0.69) 0.117 1.90 (0.85, 4.22)
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